⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 28, 2026JAMA Internal Medicine

Policy and Design Considerations for Most-Favored-Nation Drug Pricing

Matthew Vogel Olivier J. Wouters

View at Publisher

Ask AI

Bookmark

Share

Abstract

This Viewpoint discusses most-favored-nation drug pricing and how to strengthen this type of drug pricing in Medicare.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vogel et al. (2026) studied this question.

synapsesocial.com/papers/6abdf75e66f3754618513d2d https://doi.org/10.1001/jamainternmed.2026.4520

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1‘Most Favored Nation’ Drug Pricing: An Idea To What End?Original Research · 2026 · 4 citations
2‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has ComeOriginal Research · 2026 · 5 citations
3‘Most Favored Nation’ Policies And Value-Based Drug Pricing: A European ViewOriginal Research · 2026 · 4 citations
4Reforming Drug Pricing: Institutional Lessons from Most Favored Nation (MFN) and Value‐Based Care (VBC) Across Three Health Systems2025
5Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countriesOriginal Research · 2026

More related papers

Balancing Innovation, Access, and Equity in Drug Pricing: Comparative Institutional Lessons for Advancing Universal Health Coverage2025
Novel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks2026
Medicaid access to Most Favored Nation through the Pfizer agreement: The unanswered issues2026

More from JAMA Internal Medicine

Video Decision Support and Advance Care Planning in Older Adults With Advanced Kidney DiseaseThu,
Time to Measure the Outcomes of What Nurses Really DoMon,